ERBB2 and lung cancer: Again in 2022, following results from the DESTINY‐Lung02 trial, T‐DXd received FDA approval for the treatment of unresectable or metastatic nonsmall cell lung cancer in adult patients with HER2‐overexpression or HER2 mutations.71